Vale S.A. Sponsored ADR (VALE.US) Q3 revenue exceeds expectations, net profit year-on-year increases by 78%.
Global iron ore giant Vale announced that its third-quarter performance in 2025 exceeded expectations.
Global iron ore giant Vale S.A. Sponsored ADR (VALE.US) announced better-than-expected performance in the third quarter of 2025. The financial report shows that Vale S.A. Sponsored ADR's Q3 revenue increased by 9% year-on-year to $10.42 billion, higher than the analysts' general expectation of $10.33 billion. Net profit attributable to shareholders was $2.744 billion, a 78% increase year-on-year, exceeding the analysts' general expectation of $2.1 billion. Pro forma EBITDA was $4.399 billion, a 17% year-on-year increase; adjusted EBITDA was $4.369 billion, a 21% year-on-year increase, primarily due to higher sales volumes and improved cost efficiency.
By division, the iron ore division had revenue of $8.423 billion, with adjusted EBITDA of $3.972 billion; the energy transition metals division had revenue of $1.997 billion, with adjusted EBITDA of $687 million.
The company's CEO, Gustavo Pimenta, said, "Iron ore production reached its highest quarterly level since 2018, while copper achieved its best performance in the third quarter since 2019, and we continue to improve cost competitiveness in nickel."
Vale S.A. Sponsored ADR expects that the integrated copper cost in 2025 will be between $1,000 and $1,500 per ton, lower than the previous estimate of $1,500 to $2,000 per ton; and the integrated nickel cost in 2025 will be between $13,000 and $14,000 per ton, lower than the previous estimate of $14,000 to $15,500 per ton.
 Related Articles 
.png)
Through the research and development day of ABBISKO-B(02256), we can see the depth and breadth of its creation of innovative FIC/BIC pipelines.

HK Stock Market Move  | China Railway (00390) plunges more than 4% in the afternoon, with net profit down 14.97% year-on-year in the first three quarters, and the decline in performance narrows in the third quarter.

SUNSHINE PHARMA (06887) domestically approved for clinical trials of in-house developed Hepatitis B nucleic acid new drug.
Through the research and development day of ABBISKO-B(02256), we can see the depth and breadth of its creation of innovative FIC/BIC pipelines.
.png)
HK Stock Market Move  | China Railway (00390) plunges more than 4% in the afternoon, with net profit down 14.97% year-on-year in the first three quarters, and the decline in performance narrows in the third quarter.

SUNSHINE PHARMA (06887) domestically approved for clinical trials of in-house developed Hepatitis B nucleic acid new drug.

RECOMMEND

First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025

Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025

Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025


